Timed GDNF gene therapy using an immune-evasive gene switch promotes long distance axon regeneration.

R. Eggers, Fred De Winter, S.A. Hoyng, Rob C Hoeben, M.J. Malessy, M Tannemaat, J. Verhaagen

Research output: Contribution to journal/periodicalArticleScientificpeer-review

32 Citations (Scopus)

Abstract

Neurosurgical repair in patients with proximal nerve lesions results in unsatisfactory recovery of function. Gene therapy for neurotrophic factors is a powerful strategy to promote axon regeneration. Glial cell line-derived neurotrophic factor (GDNF) gene therapy promotes motor neuron survival and axon outgrowth; however, uncontrolled delivery of GDNF results in axon
entrapment. We report that time-restricted GDNF expression (1 month) using an immune-evasive doxycycline-inducible gene switch attenuated local axon entrapment in avulsed reimplanted ventral spinal roots, was sufficient to promote long-term motor neuron survival (24 weeks) and facilitated the recovery of compound muscle action potentials by 8 weeks. These improvements
were associated with an increase in long-distance regeneration of motor axons. In contrast, persistent GDNF expression impaired axon regeneration by inducing axon entrapment. These findings demonstrate that timed expression can resolve the deleterious effect of uncontrolled growth factor delivery and shows that inducible growth factor gene therapy can be employed to enhance the
efficacy of axon regeneration after neurosurgical repair of a proximal nerve lesion in rats. This preclinical study is an important step in the ongoing development of a neurotrophic factor gene therapy for patients with severe proximal nerve lesions.
Original languageEnglish
Pages (from-to)295-311
JournalBrain
Volume142
DOIs
Publication statusPublished - 16 Jan 2019

Fingerprint

Dive into the research topics of 'Timed GDNF gene therapy using an immune-evasive gene switch promotes long distance axon regeneration.'. Together they form a unique fingerprint.

Cite this